{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:28:27Z","timestamp":1790742507634,"version":"4.1.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T00:00:00Z","timestamp":1538956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/jac\/dky374","type":"journal-article","created":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T19:32:34Z","timestamp":1535398354000},"source":"Crossref","is-referenced-by-count":17,"title":["Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment"],"prefix":"10.1093","author":[{"given":"Nicolas","family":"Gr\u00e9goire","sequence":"first","affiliation":[{"name":"Inserm U1070, P\u00f4le Biologie Sant\u00e9, 1 rue Georges Bonnet, Poitiers, France"},{"name":"Universit\u00e9 de Poitiers, UFR M\u00e9decine-Pharmacie, 6 rue de la mil\u00e9trie, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Marchand","sequence":"additional","affiliation":[{"name":"Inserm U1070, P\u00f4le Biologie Sant\u00e9, 1 rue Georges Bonnet, Poitiers, France"},{"name":"Universit\u00e9 de Poitiers, UFR M\u00e9decine-Pharmacie, 6 rue de la mil\u00e9trie, Poitiers, France"},{"name":"CHU de Poitiers, Service de Toxicologie-Pharmacocin\u00e9tique, 2 rue de la mil\u00e9trie, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Ferrandi\u00e8re","sequence":"additional","affiliation":[{"name":"CHU de Tours, Service d\u2019anesth\u00e9sie et r\u00e9animation, 2 boulevard Tonnell\u00e9, Tours cedex 9, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigismond","family":"Lasocki","sequence":"additional","affiliation":[{"name":"CHU d\u2019Angers, Service d\u2019anesth\u00e9sie et r\u00e9animation, 4 rue Larrey, F-49100 Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Seguin","sequence":"additional","affiliation":[{"name":"CHU de Rennes, Service de r\u00e9animation chirurgicale, 2 rue Henri Le Guilloux, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micka\u00ebl","family":"Vourc\u2019h","sequence":"additional","affiliation":[{"name":"CHU de Nantes, Service d\u2019anesth\u00e9sie et r\u00e9animation, H\u00f4tel Dieu, 1 Place Alexis-Ricordeau, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Barbaz","sequence":"additional","affiliation":[{"name":"CHU de Tours, Service d\u2019anesth\u00e9sie et r\u00e9animation, 2 boulevard Tonnell\u00e9, Tours cedex 9, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gaillard","sequence":"additional","affiliation":[{"name":"CHU d\u2019Angers, Service d\u2019anesth\u00e9sie et r\u00e9animation, 4 rue Larrey, F-49100 Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoann","family":"Launey","sequence":"additional","affiliation":[{"name":"CHU de Rennes, Service de r\u00e9animation chirurgicale, 2 rue Henri Le Guilloux, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Asehnoune","sequence":"additional","affiliation":[{"name":"CHU de Nantes, Service d\u2019anesth\u00e9sie et r\u00e9animation, H\u00f4tel Dieu, 1 Place Alexis-Ricordeau, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Couet","sequence":"additional","affiliation":[{"name":"Inserm U1070, P\u00f4le Biologie Sant\u00e9, 1 rue Georges Bonnet, Poitiers, France"},{"name":"Universit\u00e9 de Poitiers, UFR M\u00e9decine-Pharmacie, 6 rue de la mil\u00e9trie, Poitiers, France"},{"name":"CHU de Poitiers, Service de Toxicologie-Pharmacocin\u00e9tique, 2 rue de la mil\u00e9trie, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Mimoz","sequence":"additional","affiliation":[{"name":"Inserm U1070, P\u00f4le Biologie Sant\u00e9, 1 rue Georges Bonnet, Poitiers, France"},{"name":"Universit\u00e9 de Poitiers, UFR M\u00e9decine-Pharmacie, 6 rue de la mil\u00e9trie, Poitiers, France"},{"name":"CHU de Poitiers, Service des Urgences \u2013 SAMU 86 \u2013 SMUR, 2 rue de la mil\u00e9trie, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,10,8]]},"reference":[{"key":"key\n\t\t\t\t20181008101234279_dky374-B1","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","article-title":"Pharmacokinetic issues for antibiotics in the critically ill patient","volume":"37","author":"Roberts","year":"2009","journal-title":"Crit Care Med"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B2","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2165\/00003495-200767100-00008","article-title":"Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia","volume":"67","author":"Hair","year":"2007","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B3","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"Dvorchik","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1128\/AAC.46.1.31-33.2002","article-title":"Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers","volume":"46","author":"Wise","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B5","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1128\/AAC.01433-10","article-title":"Protein binding: do we ever learn?","volume":"55","author":"Zeitlinger","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1128\/AAC.36.2.318","article-title":"Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers","volume":"36","author":"Woodworth","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B7","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.2174\/138920111798808211","article-title":"The effect of critical illness on drug distribution","volume":"12","author":"Gonzalez","year":"2011","journal-title":"Curr Pharm Biotechnol"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B8","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/cid\/cit582","article-title":"Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia","volume":"57","author":"Falcone","year":"2013","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B10","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1128\/AAC.00247-06","article-title":"Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers","volume":"50","author":"Benvenuto","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B11","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B12","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jac\/46.4.523","article-title":"Development of daptomycin for Gram-positive infections","volume":"46","author":"Tally","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B13","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1517\/13543784.8.8.1223","article-title":"Daptomycin: a novel agent for Gram-positive infections","volume":"8","author":"Tally","year":"1999","journal-title":"Expert Opin Investig Drugs"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B14","doi-asserted-by":"crossref","first-page":"258","DOI":"10.5414\/CNP63258","article-title":"Characteristics of population with normal serum creatinine impaired renal function and: the validation of a MDRD formula in a healthy general population","volume":"63","author":"Kang","year":"2005","journal-title":"Clin Nephrol"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1515\/CCLM.2011.005","article-title":"Determination of daptomycin in human plasma by liquid chromatography-tandem mass spectrometry. Clinical application","volume":"49","author":"Verdier","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B16","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1128\/AAC.00589-08","article-title":"In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers","volume":"52","author":"Kim","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/psp4.12161","article-title":"Model evaluation of continuous data pharmacometric models: metrics and graphics","volume":"6","author":"Nguyen","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B18","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1124\/dmd.105.008326","article-title":"Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes","volume":"34","author":"Zandvliet","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B19","volume-title":"Clinical Pharmacokinetics: Concepts and Applications","author":"Rowland","year":"1995"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1469-0691.2006.01455.x","article-title":"EUCAST technical note on daptomycin","volume":"12","author":"EUCAST Steering Committee","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B21","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1128\/AAC.45.3.845-851.2001","article-title":"Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection","volume":"45","author":"Louie","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13054-018-1940-1","article-title":"Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study","volume":"22","author":"Braune","year":"2018","journal-title":"Crit Care"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B23","author":"EUCAST"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ijantimicag.2013.06.006","article-title":"Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections","volume":"42","author":"Di Paolo","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B25","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s10156-013-0559-z","article-title":"Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?","volume":"19","author":"Falcone","year":"2013","journal-title":"J Infect Chemother"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B26","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1128\/AAC.48.8.2799-2807.2004","article-title":"Population pharmacokinetics of daptomycin","volume":"48","author":"Dvorchik","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B27","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/14656566.2018.1479397","article-title":"Combatting resistant enterococcal infections: a pharmacotherapy review","volume":"19","author":"Mercuro","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B28","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1517\/13543784.13.9.1159","article-title":"Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections","volume":"13","author":"Eisenstein","year":"2004","journal-title":"Expert Opin Investig Drugs"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1067\/mcp.2002.121829","article-title":"Changes in plasma protein binding have little clinical relevance","volume":"71","author":"Benet","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B30","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1046\/j.1365-2885.2002.00442.x","article-title":"Free drug fraction vs free drug concentration: a matter of frequent confusion","volume":"25","author":"Toutain","year":"2002","journal-title":"J Vet Pharmacol Ther"},{"key":"key\n\t\t\t\t20181008101234279_dky374-B31","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1128\/AAC.02967-15","article-title":"Evaluation of daptomycin exposure and efficacy and safety endpoints to support risk-versus-benefit considerations","volume":"60","author":"Bhavnani","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dky374\/25953094\/dky374.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T21:11:59Z","timestamp":1571778719000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/advance-article\/doi\/10.1093\/jac\/dky374\/5123550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,8]]},"references-count":31,"URL":"https:\/\/doi.org\/10.1093\/jac\/dky374","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,8]]}}}